{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:46:51Z","timestamp":1793666811887,"version":"4.5.1"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) significantly affects patients\u2019 quality of life and represents a high economic burden for health systems. Given the lack of safe and effective treatments for PD, drug repositioning seeks to offer new medication alternatives, reducing research time and costs compared to the traditional drug development strategy. This review aimed to collect evidence of drugs proposed as candidates to be reused in PD and identify those with the potential to be reformulated into nanocarriers to optimize future repositioning trials. We conducted a detailed search in PubMed, Web of Science, and Scopus from January 2015 at the end of 2021, with the descriptors \u201cParkinson\u2019s disease\u201d and \u201cdrug repositioning\u201d or \u201cdrug repurposing\u201d. We identified 28 drugs as potential candidates, and six of them were found in repositioning clinical trials for PD. However, a limitation of many of these drugs to achieve therapeutic success is their inability to cross the blood\u2013brain barrier (BBB), as is the case with nilotinib, which has shown promising outcomes in clinical trials. We suggest reformulating these drugs in biodegradable nanoparticles (NPs) based on lipids and polymers to perform future trials. As a complementary strategy, we propose functionalizing the NPs surface by adding materials to the surface layer. Among other advantages, functionalization can promote efficient crossing through the BBB and improve the affinity of NPs towards certain brain regions. The main parameters to consider for the design of NPs targeting the central nervous system are highlighted, such as size, PDI, morphology, drug load, and Z potential. Finally, current advances in the use of NPs for Parkinson's disease are cited.<\/jats:p>","DOI":"10.1186\/s12951-022-01612-5","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T14:12:22Z","timestamp":1663251142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Repositioning of drugs for Parkinson\u2019s disease and pharmaceutical nanotechnology tools for their optimization"],"prefix":"10.1186","volume":"20","author":[{"given":"H\u00e9ctor","family":"Hern\u00e1ndez-Parra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Arturo","family":"Avalos-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Del Prado-Audelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjam\u00edn","family":"Flor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Leyva-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Sharifi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"issue":"11","key":"1612_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"GBD 2015 Neurological Disorders Collaborator Group","year":"2017","unstructured":"GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877\u201397.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1612_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.22379\/24224022244","volume":"35","author":"JS Saavedra Moreno","year":"2019","unstructured":"Saavedra Moreno JS, Mill\u00e1n PA, Buritic\u00e1 Henao OF. Introducci\u00f3n, epidemiolog\u00eda y diagn\u00f3stico de la enfermedad de Parkinson. Acta Neurol Colomb. 2019;35(1):2\u201310. https:\/\/doi.org\/10.22379\/24224022244.","journal-title":"Acta Neurol Colomb."},{"issue":"11","key":"1612_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBD 2016 Neurological Disorders Collaborator Group","year":"2018","unstructured":"GBD 2016 Neurological Disorders Collaborator Group. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939\u201353.","journal-title":"Lancet Neurol."},{"issue":"8","key":"1612_CR4","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A. Epidemiology of Parkinson\u2019s disease. J Neural Transm. 2017;124(8):901\u20135.","journal-title":"J Neural Transm"},{"issue":"28","key":"1612_CR5","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.2174\/0929867325666180719144850","volume":"26","author":"X Chen","year":"2018","unstructured":"Chen X, Gumina G, Virga KG. Recent Advances in drug repurposing for Parkinson\u2019s disease. Curr Med Chem. 2018;26(28):5340\u201362.","journal-title":"Curr Med Chem"},{"key":"1612_CR6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.csbj.2020.04.004","volume":"18","author":"D Parisi","year":"2020","unstructured":"Parisi D, Adasme MF, Sveshnikova A, Bolz SN, Moreau Y, Schroeder M. Drug repositioning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs. Comput Struct Biotechnol J. 2020;18:1043\u201355.","journal-title":"Comput Struct Biotechnol J"},{"issue":"10103","key":"1612_CR7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664\u201375.","journal-title":"Lancet"},{"issue":"12","key":"1612_CR8","doi-asserted-by":"publisher","first-page":"8505","DOI":"10.1111\/jcmm.14674","volume":"23","author":"M Rassu","year":"2019","unstructured":"Rassu M, Biosa A, Galioto M, Fais M, Sini P, Greggio E, et al. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype. J Cell Mol Med. 2019;23(12):8505\u201310.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"1612_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","volume":"77","author":"FL Pagan","year":"2020","unstructured":"Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, et al. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77(3):309\u201317.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1612_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhang L, Li L, H\u00f6lscher C. Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease. J Parkinsons Dis. 2019;9(1):157\u201371.","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"1612_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41422-019-0153-8","volume":"29","author":"A Schaffner","year":"2019","unstructured":"Schaffner A, Li X, Gomez-Llorente Y, Leandrou E, Memou A, Clemente N, et al. Vitamin B 12 modulates Parkinson\u2019s disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Res. 2019;29(4):313\u201329.","journal-title":"Cell Res"},{"issue":"11","key":"1612_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/mds.27077","volume":"32","author":"T Chotibut","year":"2017","unstructured":"Chotibut T, Meadows S, Kasanga EA, McInnis T, Cantu MA, Bishop C, et al. Ceftriaxone reduces L-dopa\u2013induced dyskinesia severity in 6-hydroxydopamine parkinson\u2019s disease model. Mov Disord. 2017;32(11):1547\u201356.","journal-title":"Mov Disord"},{"issue":"5","key":"1612_CR13","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00415-020-10291-x","volume":"268","author":"J Baskin","year":"2021","unstructured":"Baskin J, Jeon JE, Lewis SJG. Nanoparticles for drug delivery in Parkinson\u2019s disease. J Neurol. 2021;268(5):1981\u201394. https:\/\/doi.org\/10.1007\/s00415-020-10291-x.","journal-title":"J Neurol"},{"key":"1612_CR14","unstructured":"National Institute of Neurological Disorders and Stroke. Parkinson\u2019s Disease: Hope Through Research. Bethesda, Maryland; 2020. https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Hope-Through-Research\/Parkinsons-Disease-Hope-Through-Research. Accessed 21 Dec 2020."},{"issue":"6","key":"1612_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1289\/ehp.1002839","volume":"119","author":"CM Tanner","year":"2011","unstructured":"Tanner CM, Kame F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, and Parkinson\u2019s disease. Environ Health Perspect. 2011;119(6):866\u201372.","journal-title":"Environ Health Perspect"},{"issue":"9","key":"1612_CR16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3390\/ijerph13090881","volume":"13","author":"S Nandipati","year":"2016","unstructured":"Nandipati S, Litvan I. Environmental exposures and Parkinson\u2019s disease. Int J Environ Res Public Health. 2016;13(9):881.","journal-title":"Int J Environ Res Public Health"},{"issue":"87","key":"1612_CR17","first-page":"1","volume":"6","author":"A Benazzouz","year":"2014","unstructured":"Benazzouz A, Mamad O, Abedi P, Bouali-Benazzouz R, Chetrit J. Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson\u00b4s disease. Front Aging Neurosci. 2014;6(87):1\u20135.","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"1612_CR18","first-page":"363","volume":"27","author":"R Mart\u00ednez Fern\u00e1ndez","year":"2016","unstructured":"Mart\u00ednez Fern\u00e1ndez R, Gasca Salas C, S\u00e1nchez Ferro \u00c1, Obeso J\u00c1. Actualizaci\u00f3n en la enfermedad de Parkinson. Rev Med Clin Condes. 2016;27(3):363\u201379.","journal-title":"Rev Med Clin Condes"},{"issue":"7","key":"1612_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.drudis.2015.02.009","volume":"20","author":"G Leyva-G\u00f3mez","year":"2015","unstructured":"Leyva-G\u00f3mez G, Cort\u00e9s H, Maga\u00f1a JJ, Leyva-Garc\u00eda N, Quintanar-Guerrero D, Flor\u00e1n B. Nanoparticle technology for treatment of Parkinson\u2019s disease: the role of surface phenomena in reaching the brain. Drug Discov Today. 2015;20(7):824\u201337.","journal-title":"Drug Discov Today"},{"issue":"109","key":"1612_CR20","first-page":"1","volume":"10","author":"XS Zeng","year":"2018","unstructured":"Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP. Cellular and molecular basis of neurodegeneration in Parkinson disease. Front Aging Neurosci. 2018;10(109):1\u201316.","journal-title":"Front Aging Neurosci."},{"issue":"104700","key":"1612_CR21","first-page":"1","volume":"134","author":"Z Chen","year":"2020","unstructured":"Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson\u2019s disease: implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020;134(104700):1\u201318.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1612_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P. Parkinson Disease epidemiology, pathology, genetics and pathophysiology. Clin Geriatr Med. 2020;36(1):1\u201312.","journal-title":"Clin Geriatr Med"},{"issue":"4","key":"1612_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/JPD-171191","volume":"7","author":"S Brahmachari","year":"2017","unstructured":"Brahmachari S, Karuppagounder SS, Ge P, Lee S, Dawson VL, Dawson TM, et al. c-Abl and Parkinson\u2019s disease: mechanisms and therapeutic potential. J Parkinsons Dis. 2017;7(4):589.","journal-title":"J Parkinsons Dis"},{"issue":"4874","key":"1612_CR24","first-page":"1","volume":"4","author":"SS Karuppagounder","year":"2014","unstructured":"Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease. Sci Rep. 2014;4(4874):1\u20138.","journal-title":"Sci Rep"},{"issue":"1","key":"1612_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/1871527316666170602101538","volume":"17","author":"AI Abushouk","year":"2017","unstructured":"Abushouk AI, Negida A, Elshenawy RA, Zein H, Hammad AM, Menshawy A, et al. C-Abl Inhibition; a novel therapeutic target for parkinson\u2019s disease. CNS Neurol Disord Drug Targets. 2017;17(1):14\u201321.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"1612_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/erp.11.106","volume":"12","author":"P Martinez-Martin","year":"2012","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ. Quality of life and burden in caregivers for patients with Parkinson\u2019s disease: concepts, assessment and related factors. Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(2):221\u201330.","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"15","key":"1612_CR27","first-page":"1","volume":"6","author":"W Yang","year":"2020","unstructured":"Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. Current and projected future economic burden of Parkinson\u2019s disease in the U.S. NPJ Park Dis. 2020;6(15):1\u20139.","journal-title":"NPJ Park Dis."},{"issue":"8","key":"1612_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK. Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795\u2013808.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1612_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.18433\/J30H04","volume":"20","author":"A Marsot","year":"2017","unstructured":"Marsot A, Guilhaumou R, Azulay JP, Blin O. Levodopa in Parkinson\u2019s disease: a review of population pharmacokinetics\/pharmacodynamics analysis. J Pharm Pharm Sci. 2017;20:226\u201338.","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"1612_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial. JAMA Neurol. 2017;74(2):216\u201324.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1612_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40266-018-0629-0","volume":"36","author":"MD Latt","year":"2019","unstructured":"Latt MD, Lewis S, Zekry O, Fung VSC. Factors to consider in the selection of dopamine agonists for older persons with Parkinson\u2019s disease. Drugs Aging. 2019;36(3):189\u2013202. https:\/\/doi.org\/10.1007\/s40266-018-0629-0.","journal-title":"Drugs Aging"},{"issue":"16","key":"1612_CR32","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1080\/14656566.2018.1524876","volume":"19","author":"M Torti","year":"2018","unstructured":"Torti M, Vacca L, Stocchi F. Istradefylline for the treatment of Parkinson\u2019s disease: is it a promising strategy? Expert Opin Pharmacother. 2018;19(16):1821\u20138. https:\/\/doi.org\/10.1080\/14656566.2018.1524876.","journal-title":"Expert Opin Pharmacother"},{"issue":"9916","key":"1612_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340.","journal-title":"Lancet"},{"issue":"1","key":"1612_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-017-8473-7","volume":"20","author":"C Politi","year":"2018","unstructured":"Politi C, Ciccacci C, Novelli G, Borgiani P. Genetics and treatment response in Parkinson\u2019s disease: an update on pharmacogenetic studies. NeuroMolecular Med. 2018;20(1):1\u201317. https:\/\/doi.org\/10.1007\/s12017-017-8473-7.","journal-title":"NeuroMolecular Med"},{"issue":"2","key":"1612_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/138920021502140327175404","volume":"15","author":"H Alonso-Navarro","year":"2014","unstructured":"Alonso-Navarro H, Jimenez-Jimenez F, Garcia-Martin E, Agundez J. Genomic and pharmacogenomic biomarkers of Parkinson\u2019s disease. Curr Drug Metab. 2014;15(2):129\u201381.","journal-title":"Curr Drug Metab"},{"issue":"4","key":"1612_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1517\/17425255.2016.1158250","volume":"12","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2016","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Alonso-Navarro H, Garc\u00eda-Mart\u00edn E, Ag\u00fandez JAG. Advances in understanding genomic markers and pharmacogenetics of Parkinsons disease. Expert Opin Drug Metab Toxicol. 2016;12(4):433\u201348. https:\/\/doi.org\/10.1517\/17425255.2016.1158250.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"1612_CR37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2217\/pgs.14.93","volume":"15","author":"AF Schumacher-Schuh","year":"2014","unstructured":"Schumacher-Schuh AF, Rieder CRM, Hutz MH. Parkinson\u2019s disease pharmacogenomics: new findings and perspectives. Pharmacogenomics. 2014;15(9):1253\u201371.","journal-title":"Pharmacogenomics"},{"issue":"24","key":"1612_CR38","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2498\u2013508.","journal-title":"N Engl J Med"},{"issue":"12","key":"1612_CR39","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1742-1241.2011.02793.x","volume":"65","author":"K Kalinderi","year":"2011","unstructured":"Kalinderi K, Fidani L, Katsarou Z, Bostantjopoulou S. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson\u2019s disease. Int J Clin Pract. 2011;65(12):1289\u201394. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02793.x.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"1612_CR40","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u201358.","journal-title":"Mov Disord"},{"issue":"11","key":"1612_CR41","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/mds.26712","volume":"31","author":"J Nonnekes","year":"2016","unstructured":"Nonnekes J, Timmer MHM, de Vries NM, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson\u2019s disease. Mov Disord. 2016;31(11):1602\u20139. https:\/\/doi.org\/10.1002\/mds.26712.","journal-title":"Mov Disord"},{"key":"1612_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9131474","volume":"2020","author":"Z Pirto\u0161ek","year":"2020","unstructured":"Pirto\u0161ek Z, Bajenaru O, Kov\u00e1cs N, Milanov I, Relja M, Skorvanek M. Update on the management of Parkinson\u2019s disease for general neurologists. Parkinsons Dis. 2020;2020:1\u201313.","journal-title":"Parkinsons Dis"},{"issue":"6","key":"1612_CR43","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.4103\/0028-3886.217959","volume":"65","author":"M Pistacchi","year":"2017","unstructured":"Pistacchi M, Gioulis M, Sanson F, Marsala S. Wearing off: A complex phenomenon often poorly recognized in Parkinson\u2019s disease. A study with the WOQ-19 questionnaire. Neurol India. 2017;65(6):1271\u20139.","journal-title":"Neurol India"},{"issue":"21 SUPPL. 4","key":"1612_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72(21 SUPPL. 4):1\u2013136.","journal-title":"Neurology"},{"issue":"10","key":"1612_CR45","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/ene.13078","volume":"23","author":"A Antonini","year":"2016","unstructured":"Antonini A, Chaudhuri KR, Boroojerdi B, Asgharnejad M, Bauer L, Grieger F, et al. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. Eur J Neurol. 2016;23(10):1556\u201365.","journal-title":"Eur J Neurol"},{"issue":"351","key":"1612_CR46","first-page":"1","volume":"10","author":"EM Gatto","year":"2019","unstructured":"Gatto EM, Aldinio V. Impulse control disorders in Parkinson\u2019s Disease. A brief and comprehensive review. Front Neurol. 2019;10(351):1\u201319.","journal-title":"Front Neurol."},{"issue":"31","key":"1612_CR47","first-page":"1","volume":"12","author":"MA Casu","year":"2020","unstructured":"Casu MA, Mocci I, Isola R, Pisanu A, Boi L, Mulas G, et al. Neuroprotection by the immunomodulatory drug pomalidomide in the Drosophila LRRK2WD40 genetic model of Parkinson\u2019s disease. Front Aging Neurosci. 2020;12(31):1\u201313.","journal-title":"Front Aging Neurosci"},{"key":"1612_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.neuropharm.2018.08.027","volume":"147","author":"CG Parsons","year":"2019","unstructured":"Parsons CG. CNS repurposing - potential new uses for old drugs: examples of screens for Alzheimer\u2019s disease, Parkinson\u2019s disease and spasticity. Neuropharmacology. 2019;147:4\u201310.","journal-title":"Neuropharmacology"},{"issue":"8","key":"1612_CR49","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40263-018-0548-y","volume":"32","author":"D Athauda","year":"2018","unstructured":"Athauda D, Foltynie T. Drug repurposing in Parkinson\u2019s disease. CNS Drugs. 2018;32(8):747\u201361. https:\/\/doi.org\/10.1007\/s40263-018-0548-y.","journal-title":"CNS Drugs"},{"issue":"SUPPL. 1","key":"1612_CR50","doi-asserted-by":"publisher","first-page":"D1060","DOI":"10.1093\/nar\/gkq1037","volume":"39","author":"J Von Eichborn","year":"2011","unstructured":"Von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 2011;39(SUPPL. 1):D1060\u20136.","journal-title":"Nucleic Acids Res"},{"key":"1612_CR51","first-page":"49","volume":"57","author":"S Naylor","year":"2014","unstructured":"Naylor S, Schonfeld JM. Therapeutic drug repurposing, repositioning and rescue part i: overview. Drug Discovery World (DDW). 2014;57:49\u201362.","journal-title":"Drug Discovery World (DDW)."},{"issue":"4","key":"1612_CR52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","volume":"15","author":"A Talevi","year":"2020","unstructured":"Talevi A, Bellera CL. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov. 2020;15(4):397\u2013401. https:\/\/doi.org\/10.1080\/17460441.2020.1704729.","journal-title":"Expert Opin Drug Discov"},{"issue":"3\u20134","key":"1612_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ddstr.2011.06.007","volume":"8","author":"TX Witkowski","year":"2011","unstructured":"Witkowski TX. Intellectual property and other legal aspects of drug repurposing. Drug Discov Today Ther Strateg. 2011;8(3\u20134):139\u201343.","journal-title":"Drug Discov Today Ther Strateg"},{"issue":"273","key":"1612_CR54","first-page":"1","volume":"7","author":"JJ Hernandez","year":"2017","unstructured":"Hernandez JJ, Pryszlak M, Smith L, Yanchus C, Kurji N, Shahani VM, et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol. 2017;7(273):1\u20138.","journal-title":"Front Oncol"},{"issue":"4","key":"1612_CR55","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/bib\/bbr013","volume":"12","author":"JT Dudley","year":"2011","unstructured":"Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform. 2011;12(4):303\u201311.","journal-title":"Brief Bioinform"},{"issue":"22","key":"1612_CR56","first-page":"3974","volume":"27","author":"T Uenaka","year":"2018","unstructured":"Uenaka T, Satake W, Cha PC, Hayakawa H, Baba K, Jiang S, et al. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson\u2019s disease. Hum Mol Genet. 2018;27(22):3974\u201385.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"1612_CR57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1089\/adt.2017.776","volume":"15","author":"K Styczy\u0144ska-Soczka","year":"2017","unstructured":"Styczy\u0144ska-Soczka K, Zechini L, Zografos L. Validating the predicted effect of astemizole and ketoconazole using a Drosophila model of Parkinson\u2019s disease. Assay Drug Dev Technol. 2017;15(3):106\u201312.","journal-title":"Assay Drug Dev Technol"},{"issue":"1","key":"1612_CR58","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1038\/s41467-019-09494-2","volume":"10","author":"FH Siddiqi","year":"2019","unstructured":"Siddiqi FH, Menzies FM, Lopez A, Stamatakou E, Karabiyik C, Ureshino R, et al. Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nat Commun. 2019;10(1):1817.","journal-title":"Nat Commun"},{"key":"1612_CR59","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2016.08.004","volume":"48","author":"AA Poirier","year":"2016","unstructured":"Poirier AA, C\u00f4t\u00e9 M, Bourque M, Morissette M, Di Paolo T, Soulet D. Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson\u2019s disease. Neurobiol Aging. 2016;48:61\u201371.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1612_CR60","doi-asserted-by":"publisher","first-page":"8959","DOI":"10.1038\/s41598-018-27395-0","volume":"8","author":"BM Ayoub","year":"2018","unstructured":"Ayoub BM, Mowaka S, Safar MM, Ashoush N, Arafa MG, Michel HE, et al. Repositioning of omarigliptin as a once-weekly intranasal anti-parkinsonian agent. Sci Rep. 2018;8(1):8959.","journal-title":"Sci Rep"},{"issue":"1","key":"1612_CR61","doi-asserted-by":"publisher","first-page":"8336","DOI":"10.1038\/s41598-019-44803-1","volume":"9","author":"EJR Fletcher","year":"2019","unstructured":"Fletcher EJR, Jamieson AD, Williams G, Doherty P, Duty S. Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. Sci Rep. 2019;9(1):8336.","journal-title":"Sci Rep"},{"issue":"4","key":"1612_CR62","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s13311-018-0646-z","volume":"15","author":"AI Rodriguez-Perez","year":"2018","unstructured":"Rodriguez-Perez AI, Sucunza D, Pedrosa MA, Garrido-Gil P, Kulisevsky J, Lanciego JL, et al. Angiotensin type 1 receptor antagonists protect against alpha-synuclein-induced neuroinflammation and dopaminergic neuron death. Neurotherapeutics. 2018;15(4):1063\u201381. https:\/\/doi.org\/10.1007\/s13311-018-0646-z.","journal-title":"Neurotherapeutics"},{"issue":"38","key":"1612_CR63","doi-asserted-by":"publisher","first-page":"15731","DOI":"10.1074\/jbc.M117.791863","volume":"292","author":"N Amireddy","year":"2017","unstructured":"Amireddy N, Puttapaka SN, Vinnakota RL, Ravuri HG, Thonda S, Kalivendi SV. The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice. J Biol Chem. 2017;292(38):15731\u201343.","journal-title":"J Biol Chem"},{"key":"1612_CR64","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuropharm.2017.08.015","volume":"125","author":"N Katila","year":"2017","unstructured":"Katila N, Bhurtel S, Shadfar S, Srivastav S, Neupane S, Ojha U, et al. Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology. 2017;125:396\u2013407.","journal-title":"Neuropharmacology"},{"issue":"5","key":"1612_CR65","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s43440-020-00095-1","volume":"72","author":"G Ozbey","year":"2020","unstructured":"Ozbey G, Nemutlu-Samur D, Parlak H, Yildirim S, Aslan M, Tanriover G, et al. Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation. Pharmacol Rep. 2020;72(5):1397\u2013406.","journal-title":"Pharmacol Rep"},{"issue":"3","key":"1612_CR66","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","volume":"78","author":"T Simuni","year":"2021","unstructured":"Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, et al. Efficacy of nilotinib in patients with moderately advanced parkinson disease: a randomized clinical trial. JAMA Neurol. 2021;78(3):312\u201320.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1612_CR67","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/10715762.2017.1353688","volume":"51","author":"HJ Son","year":"2017","unstructured":"Son HJ, Han SH, Lee JA, Shin EJ, Hwang O. Potential repositioning of exemestane as a neuroprotective agent for Parkinson\u2019s disease. Free Radic Res. 2017;51(6):633\u201345. https:\/\/doi.org\/10.1080\/10715762.2017.1353688.","journal-title":"Free Radic Res"},{"key":"1612_CR68","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal S, Bj\u00f8rnevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. \u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease. Science (80). 2017;357:891\u20138.","journal-title":"Science (80)"},{"key":"1612_CR69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2018.12.007","volume":"294","author":"F Rinaldi","year":"2019","unstructured":"Rinaldi F, Seguella L, Gigli S, Hanieh PN, Del Favero E, Cant\u00f9 L, et al. inPentasomes: an innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice. J Control Release. 2019;294:17\u201326.","journal-title":"J Control Release"},{"issue":"6","key":"1612_CR70","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/ejn.14079","volume":"49","author":"K Bariotto dos Santos","year":"2019","unstructured":"Bariotto dos Santos K, Padovan Neto FE, Bortolanza M, dos Santos Pereria M, Raisman-Vozari R, Tumas V, et al. Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia. Eur J Neurosci. 2019;49(6):869\u201382.","journal-title":"Eur J Neurosci."},{"issue":"6","key":"1612_CR71","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/ana.24375","volume":"77","author":"LF Potts","year":"2015","unstructured":"Potts LF, Park ES, Woo JM, Dyavar Shetty BL, Singh A, Braithwaite SP, et al. Dual \u03ba-agonist\/\u03bc-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease. Ann Neurol. 2015;77(6):930\u201341.","journal-title":"Ann Neurol"},{"key":"1612_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113413","volume":"333","author":"MJ Bartlett","year":"2020","unstructured":"Bartlett MJ, Flores AJ, Ye T, Smidt SI, Dollish HK, Stancati JA, et al. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. Exp Neurol. 2020;333: 113413.","journal-title":"Exp Neurol"},{"issue":"2","key":"1612_CR73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/ars.2015.6549","volume":"25","author":"I Lastres-Becker","year":"2016","unstructured":"Lastres-Becker I, Garc\u00eda-Yag\u00fce AJ, Scannevin RH, Casarejos MJ, K\u00fcgler S, R\u00e1bano A, et al. Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson\u2019s disease. Antioxidants Redox Signal. 2016;25(2):61\u201377.","journal-title":"Antioxidants Redox Signal"},{"issue":"74","key":"1612_CR74","doi-asserted-by":"publisher","first-page":"11052","DOI":"10.1039\/C9CC04251B","volume":"55","author":"A Mahapatra","year":"2019","unstructured":"Mahapatra A, Sarkar S, Biswas SC, Chattopadhyay K. An aminoglycoside antibiotic inhibits both lipid-induced and solution-phase fibrillation of \u03b1-synuclein: In vitro. Chem Commun. 2019;55(74):11052\u20135.","journal-title":"Chem Commun"},{"issue":"1","key":"1612_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-76927-0","volume":"10","author":"F Gonz\u00e1lez Liz\u00e1rraga","year":"2020","unstructured":"Gonz\u00e1lez Liz\u00e1rraga F, Ploper D, \u00c1vila CL, Soc\u00edas SB, dos Santos-Pereria M, Mach\u00edn B, et al. CMT-3 targets different \u03b1-synuclein aggregates mitigating their toxic and inflammogenic effects. Sci Rep. 2020;10(1):1\u201317. https:\/\/doi.org\/10.1038\/s41598-020-76927-0.","journal-title":"Sci Rep."},{"issue":"41755","key":"1612_CR76","first-page":"1","volume":"7","author":"F Gonz\u00e1lez-Liz\u00e1rraga","year":"2017","unstructured":"Gonz\u00e1lez-Liz\u00e1rraga F, Soc\u00edas SB, \u00c1vila CL, Torres-Bugeau CM, Barbosa LRS, Binolfi A, et al. Repurposing doxycycline for synucleinopathies: remodelling of \u03b1-synuclein oligomers towards non-toxic parallel beta-sheet structured species. Sci Rep. 2017;7(41755):1\u201313.","journal-title":"Sci Rep"},{"key":"1612_CR77","first-page":"1","volume":"52","author":"CSF Marques","year":"2019","unstructured":"Marques CSF, Machado J\u00fanior JB, de Andrade M, Andrade LN, Dos Santos ALS, Cruz E, et al. Use of pharmaceutical nanotechnology for the treatment of leishmaniasis. J Braz Soc Trop Med. 2019;52:1\u20135.","journal-title":"J Braz Soc Trop Med."},{"issue":"4","key":"1612_CR78","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.4067\/S0717-95022018000401463","volume":"36","author":"MC Urrejola","year":"2018","unstructured":"Urrejola MC, Soto LV, Zumar\u00e1n CC, Pe\u00f1aloza JP, \u00c1lvarez B, Fuentevilla I, et al. Polymeric nanoparticle systems: structure, elaboration methods, characteristics, properties, biofunctionalization and self-assembly layer by layer technologies. Int J Morphol. 2018;36(4):1463\u201371.","journal-title":"Int J Morphol"},{"key":"1612_CR79","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijpharm.2019.01.056","volume":"559","author":"G Sharma","year":"2019","unstructured":"Sharma G, Sharma AR, Lee SS, Bhattacharya M, Nam JS, Chakraborty C. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. Int J Pharm. 2019;559:360\u201372.","journal-title":"Int J Pharm"},{"issue":"21","key":"1612_CR80","doi-asserted-by":"publisher","first-page":"9824","DOI":"10.1021\/acs.jmedchem.9b01220","volume":"62","author":"M Gupta","year":"2019","unstructured":"Gupta M, Lee HJ, Barden CJ, Weaver DF. The blood-brain barrier (BBB) score. J Med Chem. 2019;62(21):9824\u201336.","journal-title":"J Med Chem"},{"key":"1612_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119957","volume":"590","author":"E Gallardo-Toledo","year":"2020","unstructured":"Gallardo-Toledo E, Tapia-Arellano A, Celis F, Sinai T, Campos M, Kogan MJ, et al. Intranasal administration of gold nanoparticles designed to target the central nervous system: fabrication and comparison between nanospheres and nanoprisms. Int J Pharm. 2020;590: 119957. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119957.","journal-title":"Int J Pharm"},{"issue":"2","key":"1612_CR82","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/10611861003734001","volume":"19","author":"K Ulbrich","year":"2011","unstructured":"Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood\u2013brain barrier (BBB). J Drug Target. 2011;19(2):125\u201332. https:\/\/doi.org\/10.3109\/10611861003734001.","journal-title":"J Drug Target"},{"key":"1612_CR83","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Pra\u00e7a C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34\u201347.","journal-title":"J Control Release"},{"issue":"1","key":"1612_CR84","first-page":"20","volume":"15","author":"F Alavian","year":"2020","unstructured":"Alavian F, Shams N. Oral and intra-nasal administration of nanoparticles in the cerebral ischemia treatment in animal experiments: considering its advantages and disadvantages. Curr Clin Pharmacol. 2020;15(1):20.","journal-title":"Curr Clin Pharmacol"},{"issue":"1","key":"1612_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40824-019-0166-x","volume":"23","author":"D Chenthamara","year":"2019","unstructured":"Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin F-H, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1):1\u201329. https:\/\/doi.org\/10.1186\/s40824-019-0166-x.","journal-title":"Biomater Res"},{"issue":"3","key":"1612_CR86","doi-asserted-by":"publisher","first-page":"288","DOI":"10.18433\/J3NC79","volume":"12","author":"A Pires","year":"2009","unstructured":"Pires A, Fortuna A, Alves G, Falc\u00e3o A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12(3):288\u2013311.","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"1612_CR87","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1080\/10717544.2018.1501119","volume":"25","author":"J Reinholz","year":"2018","unstructured":"Reinholz J, Landfester K, Mail\u00e4nder V. The challenges of oral drug delivery via nanocarriers. Drug Deliv. 2018;25(1):1694\u2013705.","journal-title":"Drug Deliv"},{"issue":"1","key":"1612_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep10048","volume":"5","author":"M Kaiser","year":"2015","unstructured":"Kaiser M, Pereira S, Pohl L, Ketelhut S, Kemper B, Gorzelanny C, et al. Chitosan encapsulation modulates the effect of capsaicin on the tight junctions of MDCK cells. Sci Rep. 2015;5(1):1\u201314.","journal-title":"Sci Rep"},{"issue":"4","key":"1612_CR89","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1021\/bm201790s","volume":"13","author":"CF Lien","year":"2012","unstructured":"Lien CF, Moln\u00e1r \u00c9, Toman P, Tsibouklis J, Pilkington GJ, G\u00f3recki DC, et al. In vitro assessment of alkylglyceryl-functionalized chitosan nanoparticles as permeating vectors for the Blood-Brain Barrier. Biomacromolecules. 2012;13(4):1067\u201373. https:\/\/doi.org\/10.1021\/bm201790s.","journal-title":"Biomacromolecules"},{"issue":"8","key":"1612_CR90","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.addr.2007.06.008","volume":"59","author":"LM Bareford","year":"2007","unstructured":"Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59(8):748.","journal-title":"Adv Drug Deliv Rev"},{"issue":"Pt 1","key":"1612_CR91","first-page":"159","volume":"377","author":"R Joanna","year":"2004","unstructured":"Joanna R, Volker O, Inge SZ, Dick H. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377(Pt 1):159\u201369.","journal-title":"Biochem J"},{"key":"1612_CR92","doi-asserted-by":"publisher","first-page":"509","DOI":"10.18433\/jpps31788","volume":"24","author":"N Mendoza-Mu\u00f1oz","year":"2021","unstructured":"Mendoza-Mu\u00f1oz N, Urb\u00e1n-Morl\u00e1n Z, Leyva-G\u00f3mez G, De La Luz Z-Z, Pi\u00f1\u00f3n-Segundo E, Quintanar-Guerrero D. Solid lipid nanoparticles: an approach to improve oral drug delivery. J Pharm Pharm Sci. 2021;24:509\u201332.","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"1612_CR93","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.colsurfb.2007.07.015","volume":"61","author":"H Yuan","year":"2008","unstructured":"Yuan H, Huang LF, Du YZ, Ying XY, You J, Hu FQ, et al. Solid lipid nanoparticles prepared by solvent diffusion method in a nanoreactor system. Colloids Surfaces B Biointerfaces. 2008;61(2):132\u20137.","journal-title":"Colloids Surfaces B Biointerfaces"},{"issue":"12","key":"1612_CR94","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1023\/A:1016085108889","volume":"13","author":"MP Desai","year":"1996","unstructured":"Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13(12):1838\u201345.","journal-title":"Pharm Res"},{"issue":"7","key":"1612_CR95","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.drudis.2016.05.007","volume":"21","author":"M Yu","year":"2016","unstructured":"Yu M, Yang Y, Zhu C, Guo S, Gan Y. Advances in the transepithelial transport of nanoparticles. Drug Discov Today. 2016;21(7):1155\u201361.","journal-title":"Drug Discov Today"},{"issue":"12","key":"1612_CR96","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1021\/mp500439c","volume":"11","author":"AM Bannunah","year":"2014","unstructured":"Bannunah AM, Vllasaliu D, Lord J, Stolnik S. Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge. Mol Pharm. 2014;11(12):4363\u201373. https:\/\/doi.org\/10.1021\/mp500439c.","journal-title":"Mol Pharm"},{"issue":"1","key":"1612_CR97","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejpb.2014.02.013","volume":"87","author":"N Voigt","year":"2014","unstructured":"Voigt N, Henrich-Noack P, Kockentiedt S, Hintz W, Tomas J, Sabel BA. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles. Eur J Pharm Biopharm. 2014;87(1):19\u201329.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"1612_CR98","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3762\/bjnano.11.72","volume":"11","author":"SM Lombardo","year":"2020","unstructured":"Lombardo SM, Schneider M, T\u00fcreli AE, T\u00fcreli NG. Key for crossing the BBB with nanoparticles: the rational design. Beilstein J Nanotechnol. 2020;11(1):866\u201383.","journal-title":"Beilstein J Nanotechnol"},{"issue":"1\u20132","key":"1612_CR99","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijpharm.2005.11.040","volume":"310","author":"K Gao","year":"2006","unstructured":"Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm. 2006;310(1\u20132):213\u20139.","journal-title":"Int J Pharm"},{"issue":"1","key":"1612_CR100","doi-asserted-by":"publisher","first-page":"41229","DOI":"10.1002\/app.41229","volume":"132","author":"JM Hughes","year":"2015","unstructured":"Hughes JM, Budd PM, Tiede K, Lewis J. Polymerized high internal phase emulsion monoliths for the chromatographic separation of engineered nanoparticles. J Appl Polym Sci. 2015;132(1):41229. https:\/\/doi.org\/10.1002\/app.41229.","journal-title":"J Appl Polym Sci"},{"key":"1612_CR101","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jddst.2019.05.042","volume":"52","author":"ML Del Prado-Audelo","year":"2019","unstructured":"Del Prado-Audelo ML, Maga\u00f1a JJ, Mej\u00eda-Contreras BA, Borbolla-Jim\u00e9nez FV, Giraldo-Gomez DM, Pi\u00f1a-Barba MC, et al. In vitro cell uptake evaluation of curcumin-loaded PCL\/F68 nanoparticles for potential application in neuronal diseases. J Drug Deliv Sci Technol. 2019;52:905\u201314.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1612_CR102","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.2147\/IJN.S132780","volume":"12","author":"S Shen","year":"2017","unstructured":"Shen S, Wu Y, Liu Y, Wu D. High drug-loading nanomedicines: progress, current status, and prospects. Int J Nanomedicine. 2017;12:4085.","journal-title":"Int J Nanomedicine"},{"issue":"12","key":"1612_CR103","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1021\/ja909475m","volume":"132","author":"Y Shen","year":"2010","unstructured":"Shen Y, Jin E, Zhang B, Murphy CJ, Sui M, Zhao J, et al. Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. J Am Chem Soc. 2010;132(12):4259\u201365.","journal-title":"J Am Chem Soc"},{"issue":"5","key":"1612_CR104","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s13346-019-00622-5","volume":"9","author":"K Nigam","year":"2019","unstructured":"Nigam K, Kaur A, Tyagi A, Nematullah M, Khan F, Gabrani R, et al. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. Drug Deliv Transl Res. 2019;9(5):879\u201390. https:\/\/doi.org\/10.1007\/s13346-019-00622-5.","journal-title":"Drug Deliv Transl Res"},{"key":"1612_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.05.001","volume":"103","author":"MS Deepika","year":"2019","unstructured":"Deepika MS, Thangam R, Sheena TS, Vimala RTV, Sivasubramanian S, Jeganathan K, et al. Dual drug loaded PLGA nanospheres for synergistic efficacy in breast cancer therapy. Mater Sci Eng C. 2019;103: 109716.","journal-title":"Mater Sci Eng C"},{"issue":"3","key":"1612_CR106","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/pharmaceutics10030086","volume":"10","author":"A Bhakay","year":"2018","unstructured":"Bhakay A, Rahman M, Dave RN, Bilgili E. Bioavailability enhancement of poorly water-soluble drugs via nanocomposites: formulation-processing aspects and challenges. Pharmaceutics. 2018;10(3):86.","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"1612_CR107","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijpharm.2006.01.008","volume":"312","author":"P Kocbek","year":"2006","unstructured":"Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm. 2006;312(1\u20132):179\u201386.","journal-title":"Int J Pharm"},{"issue":"6","key":"1612_CR108","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.addr.2009.03.009","volume":"61","author":"P Aggarwal","year":"2009","unstructured":"Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009;61(6):428.","journal-title":"Adv Drug Deliv Rev"},{"issue":"22","key":"1612_CR109","doi-asserted-by":"publisher","first-page":"8168","DOI":"10.1021\/ja042898o","volume":"127","author":"P Roach","year":"2005","unstructured":"Roach P, Farrar D, Perry CC. Interpretation of protein adsorption: surface-induced conformational changes. J Am Chem Soc. 2005;127(22):8168\u201373. https:\/\/doi.org\/10.1021\/ja042898o.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"1612_CR110","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","volume":"307","author":"DE Owens","year":"2006","unstructured":"Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93\u2013102.","journal-title":"Int J Pharm"},{"issue":"2","key":"1612_CR111","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0939-6411(02)00081-4","volume":"54","author":"A Gessner","year":"2002","unstructured":"Gessner A, Lieske A, Paulke BR, M\u00fcller RH. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm. 2002;54(2):165\u201370.","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"1612_CR112","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1073\/pnas.0608582104","volume":"104","author":"T Cedervall","year":"2007","unstructured":"Cedervall T, Lynch I, Lindman S, Bergg\u00e5rd T, Thulin E, Nilsson H, et al. Understanding the nanoparticle-protein corona using methods to quntify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A. 2007;104(7):2050\u20135. https:\/\/doi.org\/10.1073\/pnas.0608582104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1612_CR113","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/gels6010006","volume":"6","author":"F Pinelli","year":"2020","unstructured":"Pinelli F, Perale G, Rossi F. Coating and functionalization strategies for nanogels and nanoparticles for selective drug delivery. Gels. 2020;6(1):6.","journal-title":"Gels"},{"issue":"3","key":"1612_CR114","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.biomaterials.2012.10.003","volume":"34","author":"W Du","year":"2013","unstructured":"Du W, Fan Y, Zheng N, He B, Yuan L, Zhang H, et al. Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials. 2013;34(3):794\u2013806.","journal-title":"Biomaterials"},{"issue":"1","key":"1612_CR115","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/10717544.2019.1636420","volume":"26","author":"S Tang","year":"2019","unstructured":"Tang S, Wang A, Yan X, Chu L, Yang X, Song Y, et al. Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson\u2019s disease. Drug Deliv. 2019;26(1):700\u20137.","journal-title":"Drug Deliv"},{"issue":"6","key":"1612_CR116","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s004010050468","volume":"91","author":"B Leveugle","year":"1996","unstructured":"Leveugle B, Faucheux BA, Bouras C, Nillesse N, Spik G, Hirsch EC, et al. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson\u2019s disease cases. Acta Neuropathol. 1996;91(6):566\u201372.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1612_CR117","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/nano8030178","volume":"8","author":"A Lopalco","year":"2018","unstructured":"Lopalco A, Cutrignelli A, Denora N, Lopedota A, Franco M, Laquintana V. Transferrin functionalized liposomes loading dopamine HCl: development and permeability studies across an in vitro model of human blood-brain barrier. Nanomaterials. 2018;8(3):178.","journal-title":"Nanomaterials"},{"issue":"10","key":"1612_CR118","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/cns.12580","volume":"22","author":"YS Kang","year":"2016","unstructured":"Kang YS, Jung HJ, Oh JS, Song DY. Use of PEGylated immunoliposomes to deliver dopamine across the blood-brain barrier in a rat model of Parkinson\u2019s disease. CNS Neurosci Ther. 2016;22(10):817\u201323.","journal-title":"CNS Neurosci Ther"},{"issue":"8","key":"1612_CR119","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.nano.2018.08.004","volume":"14","author":"V Sridhar","year":"2018","unstructured":"Sridhar V, Gaud R, Bajaj A, Wairkar S. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson\u2019s disease. Nanomed Nanotechnol Biol Med. 2018;14(8):2609\u201318.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"4","key":"1612_CR120","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.nano.2018.01.020","volume":"14","author":"K Hu","year":"2018","unstructured":"Hu K, Chen X, Chen W, Zhang L, Li J, Ye J, et al. Neuroprotective effect of gold nanoparticles composites in Parkinson\u2019s disease model. Nanomed Nanotechnol Biol Med. 2018;14(4):1123\u201336.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"10","key":"1612_CR121","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s11095-013-1005-8","volume":"30","author":"R Huang","year":"2013","unstructured":"Huang R, Ma H, Guo Y, Liu S, Kuang Y, Shao K, et al. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of parkinson\u2019s disease. Pharm Res. 2013;30(10):2549\u201359.","journal-title":"Pharm Res"},{"key":"1612_CR122","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jddst.2018.08.016","volume":"48","author":"S Ray","year":"2018","unstructured":"Ray S, Sinha P, Laha B, Maiti S, Bhattacharyya UK, Nayak AK. Polysorbate 80 coated crosslinked chitosan nanoparticles of ropinirole hydrochloride for brain targeting. J Drug Deliv Sci Technol. 2018;48:21\u20139.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1612_CR123","doi-asserted-by":"publisher","first-page":"10453","DOI":"10.2147\/IJN.S272831","volume":"15","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Xiong S, Liu P, Liu W, Wang Q, Liu Y, et al. Polymeric nanoparticles-based brain delivery with improved therapeutic efficacy of ginkgolide B in Parkinson\u2019s disease. Int J Nanomedicine. 2020;15:10453\u201367.","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"1612_CR124","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ejps.2012.12.007","volume":"48","author":"MD Shadab","year":"2013","unstructured":"Shadab MD, Khan RA, Mustafa G, Chuttani K, Baboota S, Sahni JK, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci. 2013;48(3):393\u2013405.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"1612_CR125","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5607\/en.2014.23.3.246","volume":"23","author":"PY Gambaryan","year":"2014","unstructured":"Gambaryan PY, Kondrasheva IG, Severin ES, Guseva AA, Kamensky AA. Increasing the effciency of parkinson\u2019s disease treatment using a poly(lactic-co-glycolic acid) (PLGA) based L-DOPA delivery system. Exp Neurobiol. 2014;23(3):246\u201352.","journal-title":"Exp Neurobiol"},{"issue":"46","key":"1612_CR126","doi-asserted-by":"publisher","first-page":"39557","DOI":"10.1021\/acsami.8b17224","volume":"10","author":"C Fernandes","year":"2018","unstructured":"Fernandes C, Martins C, Fonseca A, Nunes R, Matos MJ, Silva R, et al. PEGylated PLGA nanoparticles as a smart carrier to increase the cellular uptake of a coumarin-based monoamine oxidase B inhibitor. ACS Appl Mater Interfaces. 2018;10(46):39557\u201369.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"9","key":"1612_CR127","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/jgm.1361","volume":"11","author":"R Huang","year":"2009","unstructured":"Huang R, Han L, Li J, Ren F, Ke W, Jiang C, et al. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med. 2009;11(9):754\u201363. https:\/\/doi.org\/10.1002\/jgm.1361.","journal-title":"J Gene Med"},{"issue":"2","key":"1612_CR128","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1021\/acs.molpharmaceut.8b00809","volume":"16","author":"Y Song","year":"2019","unstructured":"Song Y, Shi Y, Zhang L, Hu H, Zhang C, Yin M, et al. Synthesis of CSK-DEX-PLGA nanoparticles for the oral delivery of exenatide to improve its mucus penetration and intestinal absorption. Mol Pharm. 2019;16(2):518\u201332. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00809.","journal-title":"Mol Pharm"},{"issue":"7","key":"1612_CR129","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/03639045.2020.1769127","volume":"46","author":"B Kandilli","year":"2020","unstructured":"Kandilli B, Ugur Kaplan AB, Cetin M, Taspinar N, Ertugrul MS, Aydin IC, et al. Carbamazepine and levetiracetam-loaded PLGA nanoparticles prepared by nanoprecipitation method: in vitro and in vivo studies. Drug Dev Ind Pharm. 2020;46(7):1063\u201372. https:\/\/doi.org\/10.1080\/03639045.2020.1769127.","journal-title":"Drug Dev Ind Pharm"},{"key":"1612_CR130","unstructured":"CN104055735A. Semaglutide liposome and preparation method thereof. 2013. p. 1\u201321. https:\/\/patents.google.com\/patent\/CN104055735A\/en. Accessed 28 Feb 2021."},{"key":"1612_CR131","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.foodhyd.2018.12.020","volume":"92","author":"G Liu","year":"2019","unstructured":"Liu G, Yang J, Wang Y, Liu X, Guan LL, Chen L. Protein-lipid composite nanoparticles for the oral delivery of vitamin B 12: impact of protein succinylation on nanoparticle physicochemical and biological properties. Food Hydrocoll. 2019;92:189\u201397.","journal-title":"Food Hydrocoll"},{"key":"1612_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101574","volume":"56","author":"SK Sadozai","year":"2020","unstructured":"Sadozai SK, Khan SA, Karim N, Becker D, Steinbr\u00fcck N, Gier S, et al. Ketoconazole-loaded PLGA nanoparticles and their synergism against Candida albicans when combined with silver nanoparticles. J Drug Deliv Sci Technol. 2020;56: 101574.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"1612_CR133","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40580-014-0031-5","volume":"1","author":"U Jana","year":"2014","unstructured":"Jana U, Mohanty AK, Pal SL, Manna PK, Mohanta GP. Felodipine loaded PLGA nanoparticles: preparation, physicochemical characterization and in vivo toxicity study. Nano Converg. 2014;1(1):31.","journal-title":"Nano Converg"},{"issue":"5","key":"1612_CR134","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1208\/s12249-020-01711-2","volume":"21","author":"Y He","year":"2020","unstructured":"He Y, Zhan C, Pi C, Zuo Y, Yang S, Hu M, et al. Enhanced oral bioavailability of felodipine from solid lipid nanoparticles prepared through effervescent dispersion technique. AAPS PharmSciTech. 2020;21(5):170. https:\/\/doi.org\/10.1208\/s12249-020-01711-2.","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"1612_CR135","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3109\/10717544.2014.900153","volume":"22","author":"D Saini","year":"2015","unstructured":"Saini D, Fazil M, Ali MM, Baboota S, Ali J. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug Deliv. 2015;22(6):823\u201336. https:\/\/doi.org\/10.3109\/10717544.2014.900153.","journal-title":"Drug Deliv"},{"issue":"1","key":"1612_CR136","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejpb.2013.12.015","volume":"87","author":"PR Ravi","year":"2014","unstructured":"Ravi PR, Aditya N, Kathuria H, Malekar S, Vats R. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. Eur J Pharm Biopharm. 2014;87(1):114\u201324.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"1612_CR137","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3109\/10717544.2014.914986","volume":"23","author":"N Dudhipala","year":"2016","unstructured":"Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 2016;23(2):395\u2013404.","journal-title":"Drug Deliv"},{"issue":"5","key":"1612_CR138","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4274\/tjps.galenos.2019.76402","volume":"17","author":"N \u00d6zt\u00dcrk","year":"2020","unstructured":"\u00d6zt\u00dcrk N, Kara A, Vural \u0130. Formulation and in vitro evaluation of telmisartan nanoparticles prepared by emulsion-solvent evaporation technique. Turkish J Pharm Sci. 2020;17(5):492\u20139.","journal-title":"Turkish J Pharm Sci"},{"issue":"4","key":"1612_CR139","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3923\/jbs.2016.120.127","volume":"16","author":"R Abbasalipourkabir","year":"2016","unstructured":"Abbasalipourkabir R, Fallah M, Sedighi F, Maghsood AH, Javid S. Nanocapsulation of nitazoxanide in solid lipid nanoparticles as a new drug delivery system and in vitro release study. J Biol Sci. 2016;16(4):120\u20137.","journal-title":"J Biol Sci"},{"issue":"2","key":"1612_CR140","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/jphp.12672","volume":"69","author":"S Kumar","year":"2017","unstructured":"Kumar S, Bhanjana G, Verma RK, Dhingra D, Dilbaghi N, Kim K-H. Metformin-loaded alginate nanoparticles as an effective antidiabetic agent for controlled drug release. J Pharm Pharmacol. 2017;69(2):143\u201350.","journal-title":"J Pharm Pharmacol"},{"key":"1612_CR141","first-page":"179","volume":"11","author":"M Archibald","year":"2016","unstructured":"Archibald M, Pritchard T, Nehoff H, Rosengren RJ, Greish K, Taurin S. A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. Int J Nanomedicine. 2016;11:179\u2013201.","journal-title":"Int J Nanomedicine"},{"issue":"Pt 1","key":"1612_CR142","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ijbiomac.2017.07.064","volume":"105","author":"JJ Jayapal","year":"2017","unstructured":"Jayapal JJ, Dhanaraj S. Exemestane loaded alginate nanoparticles for cancer treatment: formulation and in vitro evaluation. Int J Biol Macromol. 2017;105(Pt 1):416\u201321.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"1612_CR143","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/jamp.2009.0759","volume":"23","author":"M Beck-Broichsitter","year":"2010","unstructured":"Beck-Broichsitter M, Gauss J, Gessler T, Seeger W, Kissel T, Schmehl T. Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles. J Aerosol Med Pulm Drug Deliv. 2010;23(1):47\u201357.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"45","key":"1612_CR144","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6528\/ab373e","volume":"30","author":"IV Valle","year":"2019","unstructured":"Valle IV, Machado ME, Araujo CDCB, Da Cunha-Junior EF, Da Silva PJ, Torres-Santos EC, et al. Oral pentamidine-loaded poly(d, l-lactic-co-glycolic) acid nanoparticles: an alternative approach for leishmaniasis treatment. Nanotechnology. 2019;30(45): 455102.","journal-title":"Nanotechnology"},{"issue":"1","key":"1612_CR145","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/21691401.2019.1596923","volume":"47","author":"G Omarch","year":"2019","unstructured":"Omarch G, Kippie Y, Mentor S, Ebrahim N, Fisher D, Murilla G, et al. Comparative in vitro transportation of pentamidine across the blood-brain barrier using polycaprolactone nanoparticles and phosphatidylcholine liposomes. Artif Cells Nanomed Biotechnol. 2019;47(1):1428\u201336.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"6","key":"1612_CR146","doi-asserted-by":"publisher","first-page":"10","DOI":"10.22159\/ijap.2017v9i6.16317","volume":"9","author":"P Manimekalai","year":"2017","unstructured":"Manimekalai P, Dhanalakshmi R, Manavalan R. Preparation and characterization of ceftriaxone sodium encapsulated chitosan nanoparticles. Int J Appl Pharm. 2017;9(6):10.","journal-title":"Int J Appl Pharm"},{"issue":"05","key":"1612_CR147","first-page":"45","volume":"8","author":"SG Gattani","year":"2018","unstructured":"Gattani SG, Moon RS. Formulation and evaluation of fast dissolving tablet containing vilazodone nanocrystals for solubility and dissolution enhancement using soluplus: in vitro-in vivo study. J Appl Pharm Sci. 2018;8(05):45\u201354.","journal-title":"J Appl Pharm Sci"},{"key":"1612_CR148","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.pdpdt.2018.06.011","volume":"23","author":"VPS Jesus","year":"2018","unstructured":"Jesus VPS, Raniero L, Lemes GM, Bhattacharjee TT, Caetano J\u00fanior PC, Castilho ML. Nanoparticles of methylene blue enhance photodynamic therapy. Photodiagnosis Photodyn Ther. 2018;23:212\u20137.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1612_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2021.105060","volume":"236","author":"K Khanna","year":"2021","unstructured":"Khanna K, Sharma N, Rawat S, Khan N, Karwasra R, Hasan N, et al. Intranasal solid lipid nanoparticles for management of pain: a full factorial design approach, characterization & gamma scintigraphy. Chem Phys Lipids. 2021;236: 105060.","journal-title":"Chem Phys Lipids"},{"key":"1612_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119291","volume":"581","author":"FY Han","year":"2020","unstructured":"Han FY, Liu Y, Kumar V, Xu W, Yang G, Zhao CX, et al. Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation. Int J Pharm. 2020;581: 119291.","journal-title":"Int J Pharm"},{"issue":"4","key":"1612_CR151","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1021\/acschemneuro.6b00428","volume":"8","author":"P Kumar","year":"2017","unstructured":"Kumar P, Sharma G, Kumar R, Malik R, Singh B, Katare OP, et al. Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies. ACS Chem Neurosci. 2017;8(4):860\u20135. https:\/\/doi.org\/10.1021\/acschemneuro.6b00428.","journal-title":"ACS Chem Neurosci"},{"issue":"MAY","key":"1612_CR152","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3389\/fmicb.2016.00607","volume":"7","author":"JN Payne","year":"2016","unstructured":"Payne JN, Waghwani HK, Connor MG, Hamilton W, Tockstein S, Moolani H, et al. Novel synthesis of kanamycin conjugated gold nanoparticles with potent antibacterial activity. Front Microbiol. 2016;7(MAY):607. https:\/\/doi.org\/10.3389\/fmicb.2016.00607.","journal-title":"Front Microbiol"},{"key":"1612_CR153","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/B978-0-12-391858-1.00004-6","volume":"509","author":"R Misra","year":"2012","unstructured":"Misra R, Sahoo SK. Antibacterial activity of doxycycline-loaded nanoparticles. Methods Enzymol. 2012;509:61\u201385.","journal-title":"Methods Enzymol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01612-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-022-01612-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01612-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T15:06:29Z","timestamp":1663254389000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-022-01612-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1186\/s12951-022-01612-5","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"413"}}